VELCADE

Información principal

  • Denominación comercial:
  • VELCADE 3,5 mg POLVO LIOFILIZADO PARA INFUSI
  • Dosis:
  • 3,5 mg
  • formulario farmacéutico:
  • POLVO LIOFILIZADO PARA INFUS.INTRAVENOSA
  • Usar para:
  • Humanos
  • Tipo de medicina:
  • medicamento alopático
  • Fabricado por:
  • JANSSEN PHARMACEUTICA N.V., BELGICA.

Documentos

Localización

  • Disponible en:
  • VELCADE 3,5 mg POLVO LIOFILIZADO PARA INFUSI
    Venezuela
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • Estado de Autorización:
  • VIGENTE
  • Número de autorización:
  • E.F.35.207
  • Fecha de autorización:
  • 01-06-2006
  • última actualización:
  • 03-09-2018

Prospecto

27-6-2011

Danish Pharmacovigilance Update, 16 June 2011

Danish Pharmacovigilance Update, 16 June 2011

Among the articles in this issue of Danish Pharmacovigilance Update, you can read about the removal of contraindication for Velcade® (bortezomib) used for the treatment of multiple myeloma.

Danish Medicines Agency

10-8-2018

Bortezomib Hospira (Pfizer Europe MA EEIG)

Bortezomib Hospira (Pfizer Europe MA EEIG)

Bortezomib Hospira (Active substance: bortezomib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5515 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4207/T/10

Europe -DG Health and Food Safety

30-5-2018

Bortezomib Accord (Accord Healthcare Limited)

Bortezomib Accord (Accord Healthcare Limited)

Bortezomib Accord (Active substance: bortezomib) - Centralised - Variation - Commission Decision (2018)3460 of Wed, 30 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3984/X/8

Europe -DG Health and Food Safety

2-5-2018

VELCADE (Janssen-Cilag International NV)

VELCADE (Janssen-Cilag International NV)

VELCADE (Active substance: bortezomib) - Corrigendum - Commission Decision (2018)907 of Wed, 02 May 2018

Europe -DG Health and Food Safety